The impact of proton therapy on cardiotoxicity following radiation treatment.
Cardiotoxicity
Dosimetry
Pediatric cancer
Proton therapy
Radiation
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
accepted:
30
09
2020
pubmed:
10
10
2020
medline:
24
12
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
Cardiac disease following radiation therapy represents a major consideration in the treatment of a variety of malignancies. Damage to the heart can manifest in a variety of pathologies including ischemic cardiac disease, cardiomyopathy, valvular dysfunction, arrhythmias, and pericarditis. This damage has been shown to directly relate to cardiac radiation dose and to stem from a range of cellular pathways that are often related to fibrosis. The importance of minimizing radiation dose to the heart is especially critical in the pediatric population and when treating disease sites adjacent to the heart. Proton therapy represents a promising approach to minimize dose to normal tissues such as the heart. The cardiac dosimetry reductions due to proton therapy have been demonstrated in multiple cancers and further long-term follow-up will determine the clinical significance of these reductions to cardiac structures. Future approaches using advanced techniques such as FLASH therapy could provide even further benefit by reducing post-radiation fibrosis.
Identifiants
pubmed: 33033980
doi: 10.1007/s11239-020-02303-4
pii: 10.1007/s11239-020-02303-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
877-883Références
Robison LL, Hudson MM (2014) Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 14:61–70. https://doi.org/10.1038/nrc3634
doi: 10.1038/nrc3634
pubmed: 24304873
Hoppe BS, Flampouri S, Su Z et al (2012) Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Physi 84:449–455. https://doi.org/10.1016/j.ijrobp.2011.12.034
doi: 10.1016/j.ijrobp.2011.12.034
Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998. https://doi.org/10.1056/NEJMoa1209825
doi: 10.1056/NEJMoa1209825
pubmed: 23484825
Jacobse JN, Duane FK, Boekel NB et al (2019) Radiation dose-response for risk of myocardial infarction in breast cancer survivors. Int J Radiat Oncol Biol Phys 103:595–604. https://doi.org/10.1016/j.ijrobp.2018.10.025
doi: 10.1016/j.ijrobp.2018.10.025
pubmed: 30385276
pmcid: 6361769
van Nimwegen FA, Schaapveld M, Cutter DJ et al (2016) Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. JCO 34:235–243. https://doi.org/10.1200/JCO.2015.63.4444
doi: 10.1200/JCO.2015.63.4444
Mrotzek SM, Rassaf T, Totzeck M (2020) Cardiovascular damage associated with chest irradiation. Front Cardiovasc Med 7:41. https://doi.org/10.3389/fcvm.2020.00041
doi: 10.3389/fcvm.2020.00041
pubmed: 32266294
pmcid: 7103638
Boerma M, Hauer-Jensen M (2010) Potential targets for intervention in radiation-induced heart disease. CDT 11:1405–1412. https://doi.org/10.2174/1389450111009011405
doi: 10.2174/1389450111009011405
Taunk NK, Haffty BG, Kostis JB, Goyal S (2015) Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. https://doi.org/10.3389/fonc.2015.00039
doi: 10.3389/fonc.2015.00039
pubmed: 25741474
pmcid: 4332338
Yarnold J, Vozenin Brotons M-C (2010) Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol 97:149–161. https://doi.org/10.1016/j.radonc.2010.09.002
doi: 10.1016/j.radonc.2010.09.002
pubmed: 20888056
Rodemann HP, Bamberg M (1995) Cellular basis of radiation-induced fibrosis. Radiother Oncol 35:83–90. https://doi.org/10.1016/0167-8140(95)01540-W
doi: 10.1016/0167-8140(95)01540-W
pubmed: 7569029
Sherman ML, Datta R, Hallahan DE et al (1990) Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci 87:5663–5666. https://doi.org/10.1073/pnas.87.15.5663
doi: 10.1073/pnas.87.15.5663
pubmed: 2116003
Weigel C, Schmezer P, Plass C, Popanda O (2015) Epigenetics in radiation-induced fibrosis. Oncogene 34:2145–2155. https://doi.org/10.1038/onc.2014.145
doi: 10.1038/onc.2014.145
pubmed: 24909163
Stewart FA, Heeneman S, te Poele J et al (2006) Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE−/− mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 168:649–658. https://doi.org/10.2353/ajpath.2006.050409
doi: 10.2353/ajpath.2006.050409
pubmed: 16436678
pmcid: 1606487
Chello M (1996) Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg 4:222–226. https://doi.org/10.1016/0967-2109(96)82320-9
doi: 10.1016/0967-2109(96)82320-9
pubmed: 8861442
Murray CG, Herson J, Daly TE, Zimmerman S (1980) Radiation necrosis of the mandible: a 10 year study. Part I. Factors influencing the onset of necrosis. Int J Radiat Oncol Biol Phys 6:543–548. https://doi.org/10.1016/0360-3016(80)90380-6
doi: 10.1016/0360-3016(80)90380-6
pubmed: 7410128
Robert Stewart J, Fajardo LF (1984) Radiation-induced heart disease: an update. Prog Cardiovasc Dis 27:173–194. https://doi.org/10.1016/0033-0620(84)90003-3
doi: 10.1016/0033-0620(84)90003-3
Patel SA, Lu H-M, Nyamwanda JA et al (2017) Postmastectomy radiation therapy technique and cardiopulmonary sparing: a dosimetric comparative analysis between photons and protons with free breathing versus deep inspiration breath hold. Pract Radiat Oncol 7:e377–e384. https://doi.org/10.1016/j.prro.2017.06.006
doi: 10.1016/j.prro.2017.06.006
pubmed: 28734644
Lautenschlaeger S, Iancu G, Flatten V et al (2019) Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin’s disease. Radiat Oncol 14:157. https://doi.org/10.1186/s13014-019-1360-7
doi: 10.1186/s13014-019-1360-7
pubmed: 31477141
pmcid: 6721251
Kammerer E, Guevelou JL, Chaikh A et al (2018) Proton therapy for locally advanced breast cancer: a systematic review of the literature. Cancer Treat Rev 63:19–27. https://doi.org/10.1016/j.ctrv.2017.11.006
doi: 10.1016/j.ctrv.2017.11.006
pubmed: 29197746
Tseng YD, Cutter DJ, Plastaras JP et al (2017) Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee. Int J Radiat Oncol Biol Phys 99:825–842. https://doi.org/10.1016/j.ijrobp.2017.05.004
doi: 10.1016/j.ijrobp.2017.05.004
pubmed: 28943076
Mulrooney DA, Yeazel MW, Kawashima T et al (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606–b4606. https://doi.org/10.1136/bmj.b4606
doi: 10.1136/bmj.b4606
pubmed: 19996459
pmcid: 3266843
Aleman BMP, van den Belt-Dusebout AW, Klokman WJ et al (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. JCO 21:3431–3439. https://doi.org/10.1200/JCO.2003.07.131
doi: 10.1200/JCO.2003.07.131
Ho CK, Flampouri S, Hoppe BS (2014) Proton Therapy in the Management of Lymphoma: The. Cancer J 20:387–392. https://doi.org/10.1097/PPO.0000000000000076
doi: 10.1097/PPO.0000000000000076
pubmed: 25415683
Wolf CM, Reiner B, Kühn A et al (2020) Subclinical cardiac dysfunction in childhood cancer survivors on 10-years follow-up correlates with cumulative anthracycline dose and is best detected by cardiopulmonary exercise testing, circulating serum biomarker, speckle tracking echocardiography, and tissue Doppler imaging. Front Pediatr 8:123. https://doi.org/10.3389/fped.2020.00123
doi: 10.3389/fped.2020.00123
pubmed: 32296665
pmcid: 7136405
Hahn E, Jiang H, Ng A et al (2017) Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys 98:1116–1123. https://doi.org/10.1016/j.ijrobp.2017.03.026
doi: 10.1016/j.ijrobp.2017.03.026
pubmed: 28721895
Zhang R, Howell RM, Taddei PJ et al (2014) A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. Radiother Oncol 113:84–88. https://doi.org/10.1016/j.radonc.2014.07.003
doi: 10.1016/j.radonc.2014.07.003
pubmed: 25128084
pmcid: 4256116
Mu X, Björk-Eriksson T, Nill S et al (2005) Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol 44:554–562. https://doi.org/10.1080/02841860500218819
doi: 10.1080/02841860500218819
pubmed: 16165914
Favaudon V, Caplier L, Monceau V et al (2014) Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice. Sci Transl Med 6:245–293. https://doi.org/10.1126/scitranslmed.3008973
doi: 10.1126/scitranslmed.3008973
van Marlen P, Dahele M, Folkerts M et al (2020) Bringing FLASH to the clinic: treatment planning considerations for ultrahigh dose-rate proton beams. Int J Radiat Oncol Biol Phys 106:621–629. https://doi.org/10.1016/j.ijrobp.2019.11.011
doi: 10.1016/j.ijrobp.2019.11.011
pubmed: 31759074